Evolva has been evolving. The company best-known for its stevia-based sweetener developments and had a zillion applications it was investigating, has focused down on “three highly profitable products in the near term”: stevia, nootkatone, and resveratrol. This past week, Evolva raised gross proceeds of approximately CHF 65 million from its shareholder rights offering and CHF […]
In Switzerland, Evolva raised gross proceeds of approximately CHF 65 million from its shareholder rights offering and CHF 21 million from a recent private placement, for total gross proceeds of approximately CHF 86 million. The new registered shares were offered to existing Evolva shareholders at a subscription price of CHF 0.22 per new share. As […]
In Switzerland, Evolva has signed distribution agreements for its Veri-te resveratrol in Europe with BREKO and Natural. Finding well-matched distributors is a key strategy for driving sales of Veri-te. Both of these distributors understand high quality, branded ingredients, and work only with products backed by strong science. These new partnerships are already bearing fruit with […]
Back in September 2015, we reported that Amyris inked a multi-year agreement with the US Defense Advance Research Projects Agency, the famed DARPA that gave us everything from kevlar to the Global Positioning System and the Internet — the goal in this $35M agreement with the Biological Technologies Office was to create new research and […]
In Switzerland, Cargill and Evolva inked a major collaboration pact for the production and commercialisation of EverSweet, the next-generation stevia sweetener. This product is on track for a 2018 launch, securing its first-mover advantage. Over the next three years, principally in 2018 and 2019, Evolva expects to invest an estimated USD 60 million in the […]
In Switzerland, Yorkville Advisors Global has committed to provide up to CHF 30 million in equity financing to Evolva over a 36 month period in individual tranches of up to CHF 1,000,000 each. In exchange for the funds to be provided, Yorkville will receive Evolva shares at a price which will be determined anew each […]
In Switzerland, Evolva reached the second technical milestone under the multi-year R&D alliance with Takasago. This achievement brings the project closer to the launch of the target ingredients and prompts a total milestone payment of USD 1 million to Evolva as well as the continuation of the collaboration into the next phases. The aim of […]
In Switzerland, Evolva said that “testing is underway by the US Navy of materials fabricated from special formulation of Evolva’s resveratrol.” Evolva’s collaboration with the US Navy (NAVAIR research facility, China Lake, California) is aiming to develop novel composite materials is to focus on the development of a new class of structural composite materials engineered […]
In Switzerland, Evolva said that the US National Institute of Allergy and Infectious Diseases will sponsor studies to test Evolva’s nootkatone against mosquitoes infected with Zika virus. The study will evaluate nootkatone in multiple formulations against wild type and insecticide-resistant mosquitoes that carry the virus. Studies will be conducted at Colorado State University (CSU) in […]
In Washington, the US Food and Drug Administration issued a GRAS (generally recognized as safe) No Objection Letter for Cargill’s next-generation sweetener, EverSweet, qualifying it for use in food and beverages. EverSweet was introduced in October 2015 and is made with the same sweetness found in the stevia leaf, Reb M and Reb D. EverSweet provides […]
